Compare · AVTR vs LAB
AVTR vs LAB
Side-by-side comparison of Avantor Inc. (AVTR) and Standard BioTools Inc. (LAB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTR and LAB operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- AVTR is the larger of the two at $5.43B, about 14.9x LAB ($365.2M).
- Over the past year, AVTR is down 38.2% and LAB is down 23.0% - LAB leads by 15.3 points.
- AVTR has been more active in the news (8 items in the past 4 weeks vs 7 for LAB).
- AVTR has more recent analyst coverage (25 ratings vs 5 for LAB).
- Company
- Avantor Inc.
- Standard BioTools Inc.
- Price
- $7.95-1.79%
- $0.93+0.80%
- Market cap
- $5.43B
- $365.2M
- 1M return
- +2.32%
- +1.00%
- 1Y return
- -38.22%
- -22.97%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2011
- News (4w)
- 8
- 7
- Recent ratings
- 25
- 5
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Standard BioTools Inc.
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Latest AVTR
- SEC Form 10-Q filed by Avantor Inc.
- Avantor Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Avantor® Reports First Quarter 2026 Results
- Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Avantor® Announces Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products (BMP) & Chief Transformation Officer
- Avantor® Unifies Masterflex® Portfolio to Streamline Fluid Management from R&D to Bioprocess Manufacturing
- Avantor® Enhances U.S. Biomanufacturing Infrastructure with Expanded Stability and Microbial Testing Facility
- SEC Form 4 filed by Eck Steven W
- Avantor® to Report First Quarter 2026 Earnings on Wednesday, April 29, 2026
- Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
Latest LAB
- SEC Form DEFA14A filed by Standard BioTools Inc.
- SEC Form DEF 14A filed by Standard BioTools Inc.
- Standard BioTools Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Standard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026
- SEC Form 4 filed by Egholm Michael
- SEC Form 4 filed by Kim Hanjoon Alex
- SEC Form 4 filed by Mackay Sean
- SEC Form 10-K filed by Standard BioTools Inc.
- Director Casdin Eli was granted 52,991 shares, increasing direct ownership by 2% to 2,954,053 units (SEC Form 4)
- Director Cox Troy was granted 57,264 shares, increasing direct ownership by 18% to 376,586 units (SEC Form 4)